Biophytis S.A.
Clinical-stage biotech developing therapeutics for age-related degenerative diseases.
ALBPS | PA
Overview
Corporate Details
- ISIN(s):
- FR0012816825 (+4 more)
- LEI:
- 9695008GIE061NBGU106
- Country:
- France
- Address:
- 14 AVENUE DE L'OPERA, 75001 PARIS
- Website:
- https://www.biophytis.com/en/
Description
Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-12-03 08:00 |
Biophytis –Upcoming Potential Value Generating Milestones
|
English | 218.8 KB | ||
| 2020-11-20 08:00 |
La Cour d’appel de Paris statue en faveur de Biophytis dans le cadre du litige …
|
French | 150.6 KB | ||
| 2020-11-20 08:00 |
Paris Court of Appeal rules in Biophytis’ favor in connection with the dispute …
|
English | 188.6 KB | ||
| 2020-10-26 06:00 |
Biophytis : Inclusion du premier patient au Brésil dans COVA, un essai clinique…
|
French | 169.3 KB | ||
| 2020-10-26 06:00 |
Biophytis Enrolls First Patient in Brazil in COVA, a Multinational Phase 2/3 Cl…
|
English | 192.5 KB | ||
| 2020-10-13 19:00 |
Biophytis – Inclusion du premier patient aux Etats-Unis dans COVA, un essai cli…
|
French | 203.5 KB | ||
| 2020-10-13 19:00 |
Biophytis - First US Patient Enrolled in COVA, a Multinational Phase 2/3 Clinic…
|
English | 193.7 KB | ||
| 2020-09-30 14:04 |
Reprise de la cotation de Biophytis le 30 septembre 2020 à 15h00
|
French | 126.4 KB | ||
| 2020-09-30 14:04 |
Biophytis Trading will resume on September 30, 2020 at 3.00pm CEST
|
English | 105.0 KB | ||
| 2020-09-30 13:59 |
Biophytis announces a € 10 million capital increase through private placement
|
English | 243.8 KB | ||
| 2020-09-30 13:59 |
Biophytis annonce une augmentation de capital par placement privé de 10 million…
|
French | 243.9 KB | ||
| 2020-09-30 08:00 |
Suspension de cours des actions et des BSA de Biophytis, dans l'attente d'un no…
|
French | 126.0 KB | ||
| 2020-09-30 08:00 |
Biophytis shares and BSA trading is suspended pending a new press release
|
English | 172.2 KB | ||
| 2020-09-18 18:00 |
Biophytis publie ses résultats financiers du 1er semestre 2020 et fait le point…
|
French | 321.6 KB | ||
| 2020-09-18 18:00 |
Biophytis Reports H1 2020 Financial Results and Provides Business Update
|
English | 225.0 KB |
Automate Your Workflow. Get a real-time feed of all Biophytis S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Biophytis S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Biophytis S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-11-22 | N/A | Other | Buy | 8,443,190 | 79,365.99 EUR |
| 2020-12-16 | N/A | Other | Sell | 500,000 | 499,000.00 EUR |
| 2020-12-16 | N/A | Other | Other | 313,417 | N/A |
| 2020-04-30 | N/A | Other | Other | 2,955,701 | 177,342.06 EUR |
Peer Companies
